$15.08
(4.52%)
0.10%
Add to watchlist
Create an alert
Stocks and Shares ISABeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Company Information
About this company
Key people
John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Lai Wang
President, Global Head of Research and Development
Xiaodong Wang
Co-Founder, Non-Executive Director
Aaron Rosenberg
Chief Financial Officer
Xiaobin Wu
Chief Operating Officer
Chan Lee
Senior Vice President, General Counsel
Marcello Damiani
Chief Technology Officer
Ranjeev Krishana
Lead Non-Executive Independent Director
Olivier Brandicourt
Independent Non-Executive Director
Han Dugan
Non-Executive Independent Director
Michael J. Goller
Non-Executive Independent Director
Anthony C. Hooper
Non-Executive Independent Director
Click to see more
Key facts
- Shares in issue1.43bn
- EPICONC
- ISINUS07725L1026
- LocationSwitzerland
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$42.37bn
- Employees11,000
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.